NCT05155254: An ongoing trial by IO Biotech
This trial is ongoing. It must report results 5 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05155254 |
|---|---|
| Title | An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 17, 2022 |
| Completion date | May 30, 2025 |
| Required reporting date | May 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |